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        Remodeling of pulmonary arteries is a frequent 
structural change seen in chronic pulmonary 
arterial hypertension (PAH) (  1  –  3  ). Careful his-
tological studies of lung vessels in patients with 
PAH have shown the presence of diff  erent 
types of lesions (  4  ). Pulmonary arterial muscu-
larization, with an increase in the numbers of 
vascular smooth muscle cells and smooth mus-
cle cell hypertrophy, is seen frequently (  4  ). Mus-
cularization can be confi  ned to the lamina media, 
but lesions may extend into the intima and are 
characterized by an accumulation of smooth 
muscle cells between the endothelial cell layer 
and the elastic lamina that borders the lamina 
media (  5  ). Chronic exposure to hypoxia is the 
best studied cause of pulmonary arterial muscu-
larization, as it is thought to provide the struc-
tural basis for hypoxic vasoconstriction and 
pulmonary hypertension (  4  ). 
  PAH as a primary disease is rare (idiopathic 
PAH); however, PAH as a secondary condi-
tion is much more common (  6, 7  ). Pulmonary 
arterial remodeling, together with other fac-
tors such as vasoconstriction, are thought to 
cause progressive PAH and right ventricle dys-
function. Collectively, the structural and func-
tional changes in the heart and lung vasculature 
reduce both life quality and expectancy for 
PAH patients (  6, 7  ). There is strong circum-
stantial evidence for an immune pathogenesis 
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  Pulmonary arterial remodeling characterized by increased vascular smooth muscle density is 
a common lesion seen in pulmonary arterial hypertension (PAH), a deadly condition. Clinical 
correlation studies have suggested an immune pathogenesis of pulmonary arterial remodel-
ing, but experimental proof has been lacking. We show that immunization and prolonged 
intermittent challenge via the airways with either of two different soluble antigens induced 
severe muscularization in small- to medium-sized pulmonary arteries. Depletion of CD4  +   T 
cells, antigen-specifi  c T helper type 2 (Th2) response, or the pathogenic Th2 cytokine 
interleukin 13 signifi  cantly ameliorated pulmonary arterial muscularization. The severity of 
pulmonary arterial muscularization was associated with increased numbers of epithelial 
cells and macrophages that expressed a smooth muscle cell mitogen, resistin-like molecule 
    , but surprisingly, there was no correlation with pulmonary hypertension. Our data are the 
fi  rst to provide experimental proof that the adaptive immune response to a soluble antigen 
is suffi  cient to cause severe pulmonary arterial muscularization, and support the clinical 
observations in pediatric patients and in companion animals that muscularization repre-
sents one of several injurious events to the pulmonary artery that may collectively contrib-
ute to PAH. 362 PULMONARY ARTERIAL REMODELING AND THE TH2 RESPONSE | Daley et al.
form of PAH may have no immunogenetic origin (  14  ). 
Therefore, there is currently no direct evidence for the 
pathogenic role of the immune response for pulmonary arte-
rial remodeling and PAH. The present study describes new 
models of antigen-induced pulmonary arterial muscularization 
that demonstrate a mechanistic link between an antigen-
driven Th2 immune response and severe pulmonary arte-
rial remodeling. 
of PAH. PAH is associated with rheumatoid arthritis, sys-
temic lupus erythematosus, collagen diseases (e.g., sclero-
derma and mixed connective tissue disease), hypothyroidism, 
hyper  sensitivity pneumonitis, and infection with HIV (  8  –  10  ). 
Barst et al. and Morse et al. detected an association of MHC 
class II alleles with PAH (  11  –  13  ). Despite this, there is no 
evidence for the familial form of PAH being associated 
with specifi  c MHC class II alleles, indicating that the familial 
    Figure 1.         Severe pulmonary arterial remodeling in Asp Ag  –  exposed mice.   (A) Schematic representation of the protocol for priming and chal-
lenge (i.p., arrowheads; i.n., arrows) with Asp Ag. (B  –  G) Lung micrographs from mice exposed to PBS (B and E) or Asp Ag (C, D, F, and G) show H  & E 
staining (B  –  D) or immunohistochemistry of smooth muscle actin (SMA, brown) and von Willebrand factor (blue; E and F), or SMA (blue) and Ki67 (red; G). 
Arteries (*), airways (aw), and infl  ammatory cells (arrows) are indicated. Bars: (B and C) 75     m; (D and G) 12.5     m; (E and F) 7.5     m. Individual data, 
medians (horizontal lines), and differences between PBS- and Asp Ag  –  exposed mice (***, P   <   0.001; and **, P   <   0.01 according to the Wilcoxon U test) 
are shown for arterial remodeling scores (H) and numbers of Ki67- (I) or PCNA-expressing (J) cells in pulmonary arteries. Data were pooled from two 
independent experiments.     JEM VOL. 205, February 18, 2008 
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the response to immunization and prolonged intermittent 
challenge to a largely harmless antigen (OVA) was analyzed 
(  Fig. 2 A  ).   The OVA-exposed mice consistently showed se-
vere thickening of the arterial walls, with an increase in smooth 
muscle actin  –  expressing cells, increase in cells expressing nu-
clear Ki67, and signifi  cant changes in the cellular organiza-
tion (  Fig. 2  ; and Figs. S1 and S2, available at http://www
.jem.org/cgi/content/full/jem.20071008/DC1). Collectively, 
the data showed that severe pulmonary arterial musculariza-
tion was the result of prolonged intermittent antigen chal-
lenge in primed mice. Muscularization was detected in nearly 
one half of the microscopic view fi  elds analyzed from Asp 
Ag  –  primed and   –  challenged mice and in approximately 
one third of the view fi  elds analyzed from OVA-primed and 
-challenged mice (  Table I  ).   The complete study presented in 
this manuscript used 188 mice;   >  4,500 microscopic view fi  elds 
(Table S1, available at http://www.jem.org/cgi/content/full/
jem.20071008/DC1) and   >  38,000 smooth muscle cells were 
analyzed (  Table II  ).   
  Severe, antigen-induced pulmonary arterial remodeling 
requires the presence of CD4  +   T cells 
  To determine the mechanism by which prolonged intermittent 
exposure to antigen causes severe pulmonary arterial muscular-
ization, the eff  ect of CD4  +   T cell depletion was studied in Asp 
Ag  –  primed and   –  challenged mice (  Fig. 3  ; and Fig. S3, available 
    RESULTS   
  Severe pulmonary arterial remodeling develops 
in immunized mice given prolonged intermittent exposure 
to intranasal (i.n.)   Aspergillus fumigatus   antigen (Asp Ag) 
  We found that primed mice given i.n. Asp Ag intermittently 
for a prolonged period of time (  Fig. 1 A  ) developed severe 
thickening of the walls of small- to medium-sized pulmonary 
arteries (  Fig. 1, B  –  D and H  ).   Cells multilayered within the 
thickened wall of the remodeled pulmonary arteries expressed 
smooth muscle actin, whereas von Willebrand factor  –  expressing 
endothelial cells remained in a single-cell layer (  Fig. 1, E and F  ). 
The number of cells within the remodeled arterial walls that 
were positive for the nuclear proliferation markers Ki67 (  Fig. 1, 
G and I  ) or proliferating cell nuclear antigen (PCNA;   Fig. 1 J  ; 
and Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20071008/DC1) was increased in antigen-primed, 
challenged mice compared with saline-exposed controls. 
  Severe pulmonary arterial remodeling develops 
in immunized mice given prolonged intermittent exposure 
to aerosolized OVA 
  Exposure to soluble Asp Ag, known to have immunostimula-
tory and cell-toxic activities, could have caused pulmonary 
arterial muscularization by an adaptive immune response, 
stimulation of innate immune cells, or toxicity to lung-resi-
dent cells (  15, 16  ). To distinguish between these possibilities, 
    Figure 2.         Severe pulmonary arterial remodeling in OVA-exposed mice.   (A) Schematic representation of the protocol for priming and challenge 
(i.p., arrowheads; i.n., arrows) with OVA. (B) Lung micrographs show immunohistochemistry of smooth muscle actin (SMA, red) with hematoxylin (blue) 
counterstain from saline- or OVA-exposed mice. Arteries (*) and infl  ammatory cells (arrow) are indicated. Bars: 12.5     m. (C) Bar graphs show means and 
SEM of arterial remodeling scores in mice exposed to saline or OVA (***, P   <   0.0001 according to the Wilcoxon U test;   n   = 14  –  15 mice). Individual data, 
medians (horizontal lines), and differences between PBS- and OVA-exposed mice (**, P   <   0.01; and ***, P   <   0.001 according to the Wilcoxon U test) are 
shown for (D) numbers of Ki67  +   cells, and (E) counts, percent layered, and distribution scores of smooth muscle cells in pulmonary arteries. The data were 
pooled from two independent experiments.     364 PULMONARY ARTERIAL REMODELING AND THE TH2 RESPONSE | Daley et al.
  The Th2 response determines the severity of pulmonary 
arterial remodeling in immunized and antigen-
challenged mice 
  In keeping with the known elicitation of Th2 immune re-
sponses in wild-type mice immunized with Asp Ag or OVA 
adsorbed to Alum (  17, 18  ), we found that the severity of pul-
monary arterial remodeling was correlated with the levels of 
Th2-induced serum Igs (IgE and IgG1) and bronchoalveolar 
lavage fl  uid (BALF) cytokines (IL-5 and IL-4). This was ob-
served in immunized mice exposed to either Asp Ag (  Fig. 4 A  ; 
and Fig. S5 A, available at http://www.jem.org/cgi/content/
full/jem.20071008/DC1) or OVA (  Fig. 4 B  ; and Fig. S5, C 
and D).   No such correlation was found with Th1-dependent 
IgG2a (Fig. S5 B) or IFN-     (Fig. S5 E). 
  To test the hypothesis that the Th2 response to prolonged 
intermittent antigen exposure causes pulmonary arterial mus-
cularization, IL-4  –  defi  cient (IL-4KO) mice, known to be in-
capable of developing a polarized Th2 response to immunization 
and challenge with Asp Ag (  17  ), were examined. Antigen-
primed and -challenged IL-4KO mice developed signifi  cantly 
less severe pulmonary arterial remodeling relative to wild-
type mice (  Fig. 5  ).   
  The severity of pulmonary arterial remodeling is dependent 
on indirect effects of IL-13 
  The role of endogenous IL-13 was examined using specifi  c 
inhibitors (  19  ), with the goal of identifying a mediator 
through which the Th2 response in the lungs induces arterial 
remodeling, because IL-13 has been shown to be capable of 
mediating several diff  erent Th2 response  –  induced lung dis-
ease phenotypes (  18, 20, 21  ). Immunized mice transiently 
given an IL-13 inhibitor during the fi  rst part of the exposure 
to i.n. antigen developed signifi  cantly less severe pulmonary 
arterial remodeling compared with mice given control Ig 
(  Fig. 6  ).   These data demonstrated that endogenous IL-13 was 
necessary to induce severe pulmonary arterial remodeling. 
To test if IL-13 would be suffi   cient, naive mice were given i.n. 
recombinant IL-13 intermittently over several weeks (Fig. S6 
A, available at http://www.jem.org/cgi/content/full/jem
.20071008/DC1). These mice did not develop severe arterial 
remodeling (  Table I  ; and Fig. S6 B) despite the presence of 
at http://www.jem.org/cgi/content/full/jem.20071008/DC1).   
Mice depleted of CD4  +   T cells did not develop severe pul-
monary arterial remodeling, in contrast to mice given control 
antibody (  Fig. 3  ). Administration of control antibody to anti-
gen-primed and -challenged mice had no eff  ect on the develop-
ment of pulmonary arterial remodeling (Fig. S4). Depletion 
of CD4 T cells also caused a highly signifi  cant decrease in the 
degree of infl  ammation elicited in the lungs by Asp Ag expo-
sure (Fig. S3). 
    Table I.        Analysis of primed and antigen-challenged wild-
type mice and naive mice given recombinant IL-13 
Challenge Mice View fi  elds Score of 3
Asp Ag    a   38   
  (primed)
1,009  
  (27 per mouse)
459  
  (45%)
OVA    a   22   
  (primed)
635  
  (29 per mouse)
198  
  (31%)
IL-13    b   10   
  (naive)
197  
  (20 per mouse)
0
The number of mice examined, the number of microscopic view fi  elds scored (total 
number and mean number per mouse), and the number and percentage of view 
fi  elds given the score of 3 for severe degree of pulmonary arterial muscularization 
are shown.
  a  Primed wild-type mice were challenged with antigen and given nothing or control 
antibody.
  b  Naive wild-type mice were challenged with recombinant IL-13.
    Table II.        Extent of the analysis of pulmonary arterial 
muscularization by numerical evaluation of pulmonary artery 
smooth muscle cells 
Model Mice Arteries Smooth muscle cells
Asp Ag    a   64    b   767    c   30,571
OVA    a   19 192    d   7,532
Numbers of mice, pulmonary arteries, and smooth muscle cells that were analyzed 
are shown.
  a  Groups of mice (wild type or KO) were given saline, or primed and challenged with 
antigen and given nothing, control, or neutralizing antibody.
  b  The sections of 4 out of the 64 mice were analyzed on two separate, independent 
occasions.
  c  Number of arteries examined in 68 lung sections.
  d  Number of arteries examined in 19 lung sections.
    Figure 3.         Severe pulmonary arterial remodeling is dependent on 
the presence of CD4  +   T cells.   (A) Schematic representation of the pro-
tocol for CD4        T cell depletion (i.p., arrowheads; i.n., arrows). Bar graphs 
show means and SEM of (B) scores for arterial remodeling, (C) counts, 
(D) percent layered, and (E) distribution score of smooth muscle cells (SMC) 
in pulmonary arteries from mice primed and challenged with Asp Ag and 
given control or anti-CD4 antibody. Differences between groups (*, P   <   
0.05 according to the Wilcoxon U test;   n   = 4 mice) and mean scores de-
termined in PBS-exposed mice (horizontal lines) are indicated.     JEM VOL. 205, February 18, 2008 
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immunized and antigen-challenged mice compared with 
unimmunized controls (  Fig. 7  ).   As expected, RELM      +   cells 
were epithelial cells and macrophages (Fig. S8, available at 
http://www.jem.org/cgi/content/full/jem.20071008/DC1) 
(  23, 24  ). In some pulmonary arteries, the surrounding con-
nective tissue was also weakly positive (  Fig. 7 A  ). Consistent 
with the role of endogenous IL-4 in antigen-induced pulmo-
nary arterial remodeling (  Fig. 5  ), counts of RELM      +   cells were 
signifi  cantly lower in antigen-exposed IL-4KO mice when 
compared with wild types (  Fig. 7 B  ). 
  Antigen-induced, Th2-dependent severe pulmonary 
arterial muscularization and right ventricular systolic 
pressure (RVSP) 
  Prolonged exposure to hypoxia leads to increased pulmonary 
artery pressure that is associated with the muscularization of 
the pulmonary artery and a decrease in vascularization (  26  ). 
Because we observed dramatic pulmonary arterial muscular-
ization, the hypothesis was tested that this would cause in-
creased pulmonary arterial pressure. Immunized mice were 
randomized into two groups: one was exposed to saline and 
signifi  cant interstitial infl  ammation (Fig. S6 C). The eff  ects of 
endogenous IL-13 in immunized and antigen-challenged 
mice might be indirect by regulating Th2 responsiveness, as 
suggested by the positive correlation of pulmonary arterial 
muscularization with IL-5  –  expressing T cells, the negative 
correlation with IFN-      –  producing T cells, and no correlation 
with the numbers of CD4 T cells in the lung-draining lymph 
nodes (Fig. S7). 
  Antigen-induced, Th2-dependent severe pulmonary 
arterial muscularization and hypoxia might share 
common mediators 
  The similarity of the type of arterial remodeling induced by 
an antigen-driven Th2 immune response (  Figs. 1 and 2  ) and 
by exposure to chronic hypoxia (  22  ) raised the question of 
whether common mediators might be involved. Resistin-like 
molecule (RELM)      expression in the lungs is highly up-regu-
lated by Th2- and IL-13  –  mediated infl  ammation (  23, 24  ), as 
well as hypoxia (  25  ). Probing lung sections for RELM     ex-
pression, we found that signifi  cantly increased numbers of 
RELM      +   cells bordered the remodeled pulmonary arteries in 
    Figure 4.         Severe pulmonary arterial remodeling is associated with the development of a Th2 response in Asp Ag  –   or OVA-exposed mice.  
Individual data points are shown of arterial remodeling scores plotted against (A) serum IgE levels in mice given PBS or Asp Ag priming and challenge, or 
(B) BALF IL-5 levels in mice given saline or OVA priming and challenge. The data were analyzed by Spearman  ’  s rank correlation  test.   
    Figure 5.         The IL-4  –  dependent Th2 response induces severe pulmonary arterial remodeling.   Bar graphs show means and SEM of (A) arterial re-
modeling scores, (B) pulmonary artery smooth muscle cell (SMC) counts, (C) percent layered SMC, and (D) SMC distribution scores from wild-type mice or 
IL-4KO mice given PBS or Asp Ag priming and challenge. Groups that were signifi  cantly different from antigen-primed and -challenged wild-type mice 
(***, P   <   0.001) or from antigen-primed and -challenged IL-4KO mice (+, P   <   0.05) are indicated (Bonferroni test;   n   = 7  –  10 mice). The data were pooled 
from two independent experiments.     366 PULMONARY ARTERIAL REMODELING AND THE TH2 RESPONSE | Daley et al.
RVSP in the OVA-challenged animals that had developed 
severe pulmonary arterial remodeling (  Fig. 8  ). The saline-
exposed, immunized mice were optimal to specifi  cally probe 
the role of muscularization for the development of increased 
RVSPs because these mice did not show signs of arterial re-
modeling or infl  ammation (  Fig. 8  ; Table S2; and Fig. S9). 
The failure to detect signs of right heart hypertrophy (Table S2) 
was an independent confi  rmation of the lack of signifi  cant 
pulmonary hypertension at normoxia in the group of OVA-
exposed mice that showed pulmonary arterial muscularization. 
the other was exposed to OVA aerosols (  Fig. 8  ).   RVSP was 
determined using a technique optimized to minimize the ef-
fects of the measurement itself on heart and lung function. 
There was no correlation between RVSP and pulmonary ar-
terial remodeling (  Fig. 8  ), although the OVA-exposed mice 
showed the expected T cell responses in the lung draining 
lymph node, as well as the expected histological lesions in the 
lungs (  Fig. 8  ; Table S2; and Fig. S9, available at http://www
.jem.org/cgi/content/full/jem.20071008/DC1). Stimulation 
with hypoxia for a few minutes led to signifi  cantly increased 
    Figure 6.         Endogenous IL-13 is critical for pulmonary arterial remodeling.   (A) Schematic representation of the protocol for transient IL-13 
blockade with IL-13R    2 mouse Ig constant region (IL-13R    2-Fc) in mice primed and challenged with Asp Ag. Bar graphs show means and SEM of 
(B) arterial remodeling scores, (C) pulmonary artery smooth muscle cell (SMC) counts, (D) percent layered SMC, and (E) SMC distribution scores in mice 
given PBS or Asp Ag priming and challenge and mouse Ig or IL-13R    2-Fc. Groups that differ from antigen-exposed mice given Ig (**, P   <   0.01; ***, P   <   
0.001) or IL-13R    2-Fc (+, P   <   0.05; ++, P   <   0.01; +++, P   <   0.001) are indicated (Bonferroni test;   n   = 9  –  11 mice). The data are pooled from two indepen-
dent experiments.     
    Figure 7.         Severely remodeled pulmonary arteries are surrounded by RELM    -expressing cells.   (A) Lung micrographs show immunohistochemistry 
of goat anti-RELM     (red) counterstained with hematoxylin (blue) from mice given PBS or Asp Ag priming and challenge. Arteries (*) and airways (aw) are 
indicated. Bars, 12.5     m. (B) Bar graphs show means and SEM of counts of RELM    +   cells in wild-type or IL-4KO mice exposed to PBS, Asp Ag, saline, or 
OVA. Groups different from antigen-primed and challenged wild-type (***) or IL-4KO (+++) mice are indicated (P   <   0.001 according to the Bonferroni test; 
  n   = 5  –  10 mice). Data were pooled from two independent experiments for each antigen and mouse strain.     JEM VOL. 205, February 18, 2008 
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hypoxia (  22  ), and mice that lack vasoactive intestinal peptide 
(  35  ). An immune etiology of PAH has been suggested by el-
egant studies demonstrating the association of PAH with auto-
antibodies to nuclear or vascular antigens, and with polymorphic 
alleles of the human MHC class II complex, such as HLA-
DR3 and HLA-DQ7 (  11  –  13, 31, 36  –  39  ). The increased num-
bers of T cells, B cells, mast cells, macrophages, and dendritic 
cells, as well as the detection of infl  ammatory cytokines and 
chemokines in the lungs of patients with PAH, have further 
suggested a pathogenic role for immune or infl  ammatory pro-
cesses (  5, 40  –  45  ). Collectively, these studies give correlative 
evidence for a role of infl  ammation and the immune response 
in pulmonary arterial muscularization. 
  The study presented in this paper is the fi  rst to provide di-
rect experimental proof that the immune response can induce 
severe pulmonary arterial remodeling. Our data clearly show 
that intermittent challenge over a period of several weeks with 
two diff  erent antigens induced pulmonary arterial musculariza-
tion. Our studies demonstrate that CD4  +   T cells, the IL-4  –
  induced Th2 response, and endogenous IL-13 are requisite 
components of the mechanism that causes antigen-induced 
  severe pulmonary arterial muscularization. Curtis et al. (  46  ) 
described pulmonary arteriopathy with myointimal thickening of 
the arterial walls in immunized mice exposed to inhaled, par-
ticulate (sheep red blood cell) antigens. Immunized mice acutely 
challenged with soluble antigen develop increased vascular 
smooth muscle actin  –  positive cells surrounding pulmonary 
blood vessels (  47  ), and an increased vasoconstrictor response in 
isolated pulmonary arteries ( 48  ). Asthmatic patients and BALB/
c mice challenged with soluble antigen demonstrate increased 
vascularization of the airway mucosa (  49  ). However, severe 
arterial muscularization is not elicited (  18, 47  –  51  ). Our study 
suggests that the prolonged and intermittent antigen challenge 
schedule provides the Th2 immune response regulated signals 
for cell proliferation, or diff  erentiation of smooth muscle ac-
tin  –  positive cells, and rearrangement of the cellular organiza-
tion resulting in a severely remodeled arterial wall. 
  We show that IL-13, and likely IL-4, act indirectly by 
eliciting additional eff  ectors (soluble mediators or cells) of the 
type 2 immune response. Our results are in keeping with data 
demonstrating mild vascular remodeling in response to recom-
binant IL-13 in a particularly susceptible mouse strain (  52  ), 
and with the failure to detect severe arterial remodeling in mice 
that carry a transgene overexpressing IL-13 or IL-4 in airway 
epithelial cells (  53  –  55  ). 
  The arterial remodeling described in our studies and that 
observed in animals chronically exposed to hypoxia is highly 
similar in both morphology (the thickening and reorganiza-
tion of the smooth muscle cell constituents of the arterial wall, 
and the increase in proliferation marker  –  positive cells; references 
  22, 56  ) and in the increased expression of RELM    . Mouse 
RELM     is also named hypoxia-induced mitogenic factor 
(  25  ), because it and its human homologue (RELM    ) (  57  ) are 
mitogenic for vascular smooth muscle cells. Human RELM     
is expressed in the human lung and is elevated in hypoxia-
exposed cultured lung cells (  57  ). 
    DISCUSSION   
  The increased incidence of PAH in autoimmune diseases 
(  8  –  10  ), chronic obstructive pulmonary disease ( 27, 28 ), hyper-
sensitivity pneumonitis (  29  ), and infectious disease (  30, 31  ) 
has suggested that chronic infl  ammation provides signals that 
cause pulmonary arterial remodeling. Infl  ammation is also as-
sociated with pulmonary arterial muscularization in experi-
mental animals, e.g., rats exposed to monocrotaline (  32, 33  ), 
transgenic mice that overexpress S100A4/Mts1 (a tumor-
associated protein) in the lungs ( 34  ), animals exposed to chronic 
    Figure 8.         Relationship between RVSP and pulmonary arterial re-
modeling scores.   (A) Mice were immunized and exposed to saline or OVA 
aerosol as shown (i.p., arrowheads; i.n., arrows). (B) Data points show RVSP 
plotted against arterial remodeling scores in individual mice. The analysis by 
Spearman  ’  s rank correlation test was not signifi  cant. Symbols show RVSP in 
response to (C) normoxia, (D) acute hypoxia (10 min of breathing 10% O  2 ), 
and (E) corresponding arterial remodeling scores. Data from individual mice 
are aligned vertically; horizontal bars indicate medians. Statistical analysis 
was performed with the two-tailed, independent Wilcoxon U test. **, P   <   0.01 
for the comparison of groups excluding the outlier in the OVA group that did 
not show severe pulmonary arterial remodeling (outlier data are highlighted 
in gray; D); **, P   <   0.01 for the comparison of groups including all data (E).    368 PULMONARY ARTERIAL REMODELING AND THE TH2 RESPONSE | Daley et al.
mAb to CD4 (clone GK1.5) or control mAb i.p. 2 d before the fi  rst priming 
dose of Asp Ag. The antibody injections were repeated at 5  –  7-d intervals. 
The schedule of administration of the anti-CD4 antibody was based on the 
published effi   cacy of this antibody for depletion of naive CD4  +   T cells (  73  ). 
The mice were rested, given a fi  nal i.n. challenge, and killed 4 d later (  Fig. 3 A  ). 
Control mice were not immunized, and given PBS and no antibody. 
  At the end of the experiment, single-cell suspensions were prepared from 
one lung lobe and the spleens. The cells were examined for numbers of CD4  +   
T cells and for the ratio of CD4  +  /CD8  +   T cells using fl  ow cytometry and an 
anti-CD4 antibody labeled with peridium chlorophyll protein (PerCp; BD 
Biosciences) and an anti-CD8 antibody labeled with FITC (eBioscience). 
The data were acquired on a fl  ow cytometer (FACSCalibur) and analyzed 
with CellQuest software (both from BD Biosciences). 
  Determination of the role of IL-4 and the Th2 response.     Groups of 
IL-4  –  defi  cient (IL-4KO) and wild-type mice were given PBS or were immu-
nized and challenged i.n. with Asp Ag using the protocol outlined in   Fig. 1 A  . 
  IL-13 neutralization.     Groups of wild-type mice were given PBS or primed 
and challenged with Asp Ag (  Fig. 6 A  ). The mice were injected with IL-13 
inhibitor or control protein i.p just before the second i.n. antigen challenge 
until 2 d after the third i.n. antigen challenge (  Fig. 6 A  ). The mice were 
rested, challenged once, and killed. The following IL-13 inhibitors were 
used: (a) a soluble protein consisting of the IL-13R    2 chain fused to an Ig 
heavy chain (  18, 19, 74, 75  ) of mouse origin (IL-13R    2-Fc, 0.32-mg dose 
given daily; provided by S. Goldman, Wyeth Research, Cambridge, MA), 
and (b) a neutralizing, polyclonal rabbit anti  –  mouse IL-13 antibody (0.5  –  1-mg 
dose given every other day; reference   76  ). Each inhibitor was tested in two 
independent experiments, each of which was designed with three groups of 
mice: (a) nonimmunized mice given i.p. and i.n. PBS, (b) mice immunized 
and challenged with Asp Ag and given control Ig, and (c) mice immunized 
and challenged with Asp Ag and given IL-13 inhibitor (  Fig. 6 A  ). In each 
independent experiment, the group size was four to six mice. 
  i.n. challenge with recombinant IL-13.     The IL-13 challenge experiments 
were performed in mice housed at St. Luke  ’  s Roosevelt Hospital under G. 
Grunig  ’  s supervision. Naive wild-type mice were given control protein (BSA, 
low in endotoxin; 1% in PBS; Sigma-Aldrich) or recombinant IL-13 (5   μ  g 
per dose in a 50-  μ  l volume of PBS/BSA; PeproTech) using the schedule shown 
in Fig. S6 A. 
  Tissue recovery.     At the end of each experiment, the mice were killed by 
an overdose of ketamine/xylazine. Blood, spleens, lung draining lymph 
nodes, and BALF were obtained (  18, 50  ). The lungs were infl  ated and re-
moved into formaldehyde. In some experiments, a single lung lobe was su-
tured off   and removed into Hanks balanced salt solution before the infl  ation 
of the rest of the lungs with formaldehyde. 
  Preparation of lung sections.     Formaldehyde-fi  xed lung tissues were em-
bedded in paraffi   n, sectioned, and stained with hematoxylin and eosin (H  &  E) 
by the Pathology Core Laboratory (Columbia University) or Schering-Plough 
Biopharma. From each specimen, additional sections were cut and stored at 
room temperature for immunohistochemical staining. 
  Immunohistochemistry.     Sections of formaldehyde-fi   xed and paraffi   n-
embedded lung lobes were deparaffi   nized and rehydrated. Epitope retrieval 
was performed by boiling the sections in citrate buff  er, pH 6 (Invitrogen). 
Subsequent incubations were performed in a humidifi  ed chamber. Sections 
were reacted with hydrogen peroxide block (Lab Vision), washed, and blocked 
with 10% normal donkey serum (Jackson ImmunoResearch Laboratories). 
The sections were then incubated with the following primary antibody pairs: 
biotinylated mouse anti  –  smooth muscle actin (clone 1A4; Lab Vision) and poly-
clonal rabbit anti  –  von Willebrand factor (Chemicon); biotinylated mouse anti  –
  smooth muscle actin and monoclonal rabbit anti-Ki67 (clone SP6; Lab Vision); 
rabbit polyclonal anti  –  smooth muscle actin (Lab Vision) and biotinylated 
  In keeping with previous studies in the mouse demon-
strating that pulmonary hypertension can be measured in the 
absence of signifi  cant pulmonary arterial muscularization (  58  –  61  ), 
our studies clearly show that pulmonary arterial musculariza-
tion, even when present at a advanced degree and aff  ecting a 
signifi  cant area of the lungs, does not necessarily cause pul-
monary hypertension. Our data are supported by clinical ob-
servations in pediatric patients with a congenital heart defect 
associated with remodeling of the pulmonary arteries. In some 
of these patients, the pulmonary arterial pressure normalizes 
the day after surgical heart repair despite the presence of pul-
monary arterial muscularization (  62, 63  ). Pulmonary arterial 
muscularization and hypertension can also be caused by hel-
minth parasites such as   Schistosoma   species (  64  –  66  ) or   Dirofi  laria   
species (  67, 68  ).   D. immitis   infection of cats induces signifi  -
cant pulmonary arterial muscularization that is not necessarily 
accompanied by pulmonary hypertension (  69  ), and similar con-
clusions have been suggested in   D. immitis    –  infected dogs (  70  ). 
  Our data show for the fi  rst time that the Th2 immune 
  response to soluble antigen is suffi   cient to cause severe pul-
monary arterial muscularization. Our study suggests that the 
activation of shared mediators, such as RELM     (  23  –  25, 57  ), 
might produce similar morphological alterations in the pul-
monary arteries in response to either Th2-mediated infl  am-
mation or chronic hypoxia. These data might have implications 
for the identifi  cation of novel diagnostic and therapeutic tar-
gets for pulmonary arterial remodeling. 
  MATERIALS AND METHODS 
  Mice.     Wild-type C57BL/6 and IL-4 KO mice (  71  ) on the C57BL/6 back-
ground were purchased from the Jackson Laboratory. The mice were housed 
in specifi  c pathogen-free conditions at St. Luke  ’  s Roosevelt Hospital or 
Schering-Plough Biopharma. All experiments were performed according to 
guidelines outlined by the United States Department of Agriculture and the 
American Association of Laboratory Animal Care under the supervision of 
the Institutional Animal Care and Use Committee at St. Luke  ’  s Roosevelt 
Hospital or Schering-Plough Biopharma. 
  Model for pulmonary arterial muscularization in Asp Ag  –  primed 
and   –  challenged mice.     The mice were housed at St. Luke  ’  s Roosevelt 
Hospital for all studies that required Asp Ag priming and exposure, and the 
experiments were performed under G. Grunig  ’  s supervision. Groups of mice 
were either given PBS or primed and challenged i.n. with crude Asp Ag free 
of viable fungus (  50, 72  ). Priming consisted of two weekly i.p. injections of 
91   μ  g Asp Ag in a 100-  μ  l volume of PBS (  Fig. 1 A  ). Challenges were given 
i.n. to lightly anaesthetized mice with 100   μ  g of antigen in a 50-  μ  l volume 
of PBS. Control mice were not primed and received PBS i.p. and i.n. The 
mice were killed 4 d after the fi  nal i.n. exposure. 
  Model for pulmonary arterial muscularization in OVA-primed and 
-challenged mice.     For this part of the study, the experiments were per-
formed at Schering Plough Biopharma under R. de Waal Malefyt  ’  s supervision. 
OVA (grade V; Sigma-Aldrich) was diluted to 1 mg/ml in 0.15 M of sterile 
  saline (Sigma-Aldrich), complexed with Alum (Imject Alum; Thermo Fisher 
Scientifi  c), and injected i.p. (fi  nal dose = 50   μ  g OVA and 2 mg Alum), as 
shown in   Fig. 2 A  . Challenges with aerosolized OVA were given for 45 min at 
a concentration of 10 or 25 mg/ml (day 43 only). Mice were killed on day 44. 
  Depletion of CD4 T cells.     Groups of wild-type mice were primed and 
challenged with Asp Ag (  Fig. 3 A  ) and given 0.6 mg per mouse of a depleting JEM VOL. 205, February 18, 2008 
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actin antibody. Care was taken not to count proliferation marker  –  positive 
cells located within the arterial lumen or outside of the arterial wall. For each 
mouse, the mean number of proliferating cells (positive nuclei) per pulmo-
nary artery was determined. 
  The mean number of RELM    -positive cells that surrounded the pulmo-
nary arteries was determined in sections stained with an anti-RELM     anti-
body and counterstained with hematoxylin. For each mouse, the mean number 
of RELM    -positive cells surrounding pulmonary arteries was determined. 
  Photomicrographs.     Photomicrographs were taken using microscopes 
(Nikon) equipped with the RT SPOT digital camera/software package (Di-
agnostic Instruments, Inc.), or with the Spot RT Color 2000 camera (model 
2.2.1; Diagnostic Instruments, Inc.) and Openlab software (Improvision Inc.). 
  Assessment of the immune response.     The evaluation of the immune 
response was performed as previously described (  50  ) by determining Ig titers 
in the serum, enumerating T cells capable of producing intracellular cyto-
kines in cell suspensions from lung draining lymph nodes, and by determin-
ing cytokine concentrations in the BALF. 
  Paired antibodies and standards were purchased for mouse IgE, IgG1, 
and IgG2a (SouthernBiotech and BD Biosciences) to determine the concen-
tration of total Ig in the serum using standard ELISA assays, as previously 
  described (  50  ). 
  OVA-specifi  c IgE levels were quantitated by Luminex with a Beadlyte 
mouse Ig isotyping kit (Millipore). Data acquisition and analysis were per-
formed on a Luminex 100 machine with MasterPlex software. 
  Intracellular cytokine staining was performed on cell suspensions pre-
pared from the lung draining lymph nodes, as previously described (  50  ). The 
cells were cultured in the presence of PMA and ionomycin for 4 h, with the 
addition of Brefeldin A for the last 2 h of culture. The cells were harvested, 
fi  xed in 2% buff  ered formaldehyde, permeabilized, and stained with PE-
labeled anti  –  IL-5 and allophycocyanin-labeled anti  –  IFN-     mAbs (eBioscience). 
The cells were surface stained with FITC-labeled anti-CD8 or anti-Thy1.2 
combined with PerCp-labeled anti-CD4 mAbs. The cells were examined on 
a FACSCalibur using CellQuest software. Electronic gates were set using the 
forward and side scatter profi  les in combination with the surface labels to 
capture CD4  +   T cells. The intracellular isotype control mAbs were used to 
set the quadrants that demarcated cytokine-positive cells. 
  Cytokine levels in BALF were determined using custom mouse cyto-
kine Luminex kits (Linco) according to the manufacturer  ’  s instructions. Each 
BALF sample was analyzed in duplicate. Data acquisition and analysis was 
performed on a Luminex 100 machine with MasterPlex software. 
  Analysis of RVSP and right heart hypertrophy.     C75BL/6 wild-type 
mice were primed with OVA on Alum. The animals were randomized into 
two groups: one was given saline aerosol, and the other was given OVA aero-
sol (  Fig. 8  ). Before the measurements, the mice were color coded to obscure 
the type of exposure. The hemodynamic measurements were performed at 
Stanford University. RVSP, right ventricular function (pressure change per 
second), and heart rate were measured by jugular vein catheterization (1.4 F 
catheter; Millar Instruments Inc.) connected to a pressure transducer under 
isofl  urane anesthesia (1.5  –  2.5%, 2 liter O  2  /min) using a closed chest tech-
nique in unventilated mice, as previously described (  78  ). The right ventricu-
lar hypertrophy was evaluated by Fulton index measurements (weight of 
right ventricle/left ventricle plus septum). Pulmonary vascular reactivity was 
assessed in mice anesthetized with 1.5% isofl  urane, during which they were 
exposed to 40% O  2   (baseline) followed by 10% O  2   (hypoxia) for 10 min and 
were recovered at 40% O  2   for 10 min. 
  Statistical analysis.     Pairwise comparisons were performed using the two-
tailed Wilcoxon U test for independent datasets. Analysis of data for correla-
tion with the pulmonary arterial remodeling scores was performed using 
Spearman  ’  s rank correlation test. One-way analysis of variance, followed by 
pairwise comparisons with the Bonferroni test, was used to analyze experi-
ments comprised of multiple groups. P   <   0.05 was considered signifi  cant. 
mouse monoclonal anti-PCNA (clone PC10; Lab Vision); with appropriate 
control antibodies; or with the single primary antibodies biotinylated mono-
clonal mouse anti  –  smooth muscle actin (Lab Vision), biotinylated polyclonal 
goat anti-RELM     (R  &  D Systems), or rabbit polyclonal anti-RELM     (Ab-
cam). The antibodies were used at concentrations recommended by the 
manufacturer or at 1   μ  g/ml if there were no recommendations. The follow-
ing secondary reagents were used: alkaline phosphatase  –   or horseradish per-
oxidase  –  conjugated polyclonal donkey anti  –  rabbit antibody (Fab fragment, 
multiple absorptions; Jackson ImmunoResearch Laboratories), horseradish 
peroxidase  –  conjugated avidin (eBioscience), or alkaline phosphatase  –  conju-
gated streptavidin (Jackson ImmunoResearch Laboratories). Antibody bind-
ing was visualized using substrates for alkaline phosphatase (blue kit III, 
supplemented with levamisole to block the endogenous enzyme) and horse-
radish peroxidase (Vector NovaRed) from Vector Laboratories, producing 
blue (alkaline phosphatase) or red (horseradish peroxidase) reaction products. 
Sections stained with a single primary antibody were counterstained with 
Mayer  ’  s hematoxylin (Sigma-Aldrich). 
  Scores for pulmonary arterial remodeling and infl  ammation.     H  &  E-
stained sections were coded and randomized to obscure the group identity. 
Sections were examined with a light microscope at 200 or 400  ×   magnifi  cation. 
Random, consecutive view fi  elds were scored. 15  –  30 fi  elds per lung were scored, 
and the mean score was calculated for each parameter. 
  Pulmonary arterial remodeling was scored on small- to medium-sized 
arteries that were located close to the airways and could be examined under 
the view fi  eld given with 400  ×   magnifi  cation as follows: 1, normal; 2, thick-
ened vascular wall with intact lumen and circular media (all cells follow the 
form given by the endothelium); and 3, lumen appears to be obstructed, and 
the wall is thickened and lined with disorganized layers of cells (cells in the 
blood vessel wall assume a pattern that diff  ers from the lumen). 
  Pulmonary perivascular infl  ammation was scored on consecutive pul-
monary blood vessels as follows: 1, normal with very few infl  ammatory cells; 
2, scattered infl  ammatory cells up to two rings in depth; and 3, cuff  s of in-
fl  ammatory cells measuring three rings or more in depth. 
  Interstitial infl  ammation was scored as follows: 1, normal; 2, increased 
numbers of cells within the alveoli; and 3, consistent increase in the numbers 
of cells within the alveoli, appearance of multinucleated giant cells, and thick-
ening of the alveolar septa. 
  System for numerical analysis of pulmonary arterial remodeling.   
  The numeric analysis system was adapted from mathematical methods for the 
two-dimensional analysis of cell layers (  77  ). Lung sections stained with H  &  E 
were coded and randomized to obscure the group identity. 10  –  15 consecu-
tive small- to medium-sized pulmonary arteries that could be examined by 
the view fi  eld given by 400  ×   magnifi  cation were analyzed. Each vascular 
smooth muscle cell was analyzed for the type of neighboring cell (endothelial 
cell, smooth muscle cell, or adventitial cell) and categorized (Fig. S2) as fol-
lows: 1, the smooth muscle cell was located between an endothelial cell and 
the adventitia; 2, the smooth muscle cell was located between an endothelial 
cell and another smooth muscle cell, or between a smooth muscle cell and 
the adventitia; and 3, the smooth muscle cell was located between other 
smooth muscle cells. 
  These data were used to calculate for each lung (a) the smooth muscle 
count (number of smooth muscle cells counted/number of arteries evaluated), 
(b) the percentage of layered smooth muscle cells (mean of the percentage of 
category 3 cells present in each of the arteries examined), and (c) the mean 
smooth muscle cell distribution score     ([number of category 1 cells    ×   1 + 
number of category 2 cells   ×   2 + number of category 3 cells       ×   3]/number 
of arteries evaluated). 
  Enumeration of immunoreactive cells.     All numerical determinations 
were performed on 10  –  30 pulmonary arteries viewed at 400  ×   magnifi  ca-
tion. The group identity of the lung sections was obscured before analysis. 
  The mean number of proliferating cells was determined in sections stained 
with a proliferation marker (Ki67 or PCNA) and with an anti  –  smooth muscle 370 PULMONARY ARTERIAL REMODELING AND THE TH2 RESPONSE | Daley et al.
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